FDA Cites 22 Failed Trials in Report, Making the Case for the Phase III Gold Standard

Drug Industry Daily
The FDA compiled 22 case studies of different drugs, vaccines and devices that demonstrated promising results in Phase II studies, but later failed in larger Phase III clinical trials.

To View This Article:


Subscribe To Drug Industry Daily